Overview Study Evaluating Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose of SAM-531 Status: Completed Trial end date: 2009-02-01 Target enrollment: Participant gender: Summary The main objectives of this study is to assess the safety and tolerability of ascending single and multiple oral doses of SAM-531 in healthy subjects Phase: Phase 1 Details Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer